Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44043   clinical trials with a EudraCT protocol, of which   7319   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-001478-14
    Sponsor's Protocol Code Number:071301
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2017-03-21
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2016-001478-14
    A.3Full title of the trial
    A PROSPECTIVE, PHASE 3, OPEN LABEL, INTERNATIONAL
    MULTICENTER STUDY ON EFFICACY AND SAFETY OF PROPHYLAXIS
    WITH rVWF IN SEVERE VON WILLEBRAND DISEASE
    ÉTUDE DE PHASE 3, INTERNATIONALE, MULTICENTRIQUE, PROSPECTIVE ET EN OUVERT, ÉVALUANT L’EFFICACITÉ ET L’INNOCUITÉ D’UN TRAITEMENT PROPHYLACTIQUE PAR UN FACTEUR DE VON WILLEBRAND RECOMBINANT (FvWr) CHEZ DES PATIENTS ATTEINTS D’UNE FORME GRAVE DE LA MALADIE DE VON WILLEBRAND
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to determine the effectiveness and Safety of rVWF used to prevent bleeding episodes in patients with severe von Willebrand disease
    Étude évaluant l’efficacité et l’innocuité d’un facteur de von Willebrand recombinant (FvWr) utilisé en prévention des épidoses de saignement chez des patients atteints d’une forme grave de la maladie de von Willebrand
    A.3.2Name or abbreviated title of the trial where available
    rVWF IN PROPHYLAXIS
    A.4.1Sponsor's protocol code number071301
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBaxalta Innovations GmbH
    B.1.3.4CountryAustria
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBaxalta Innovations GmbH
    B.4.2CountryAustria
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBaxalta Innovation GmbH
    B.5.2Functional name of contact pointSanhita Abrol
    B.5.3 Address:
    B.5.3.1Street Address650 East Kendall Street
    B.5.3.2Town/ cityCambridge
    B.5.3.3Post codeMA02142
    B.5.3.4CountryUnited States
    B.5.4Telephone number+1 617 588 8128
    B.5.6E-mailsanhita.abrol1@shire.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/10/814
    D.3 Description of the IMP
    D.3.1Product nameRecombinant von Willebrand Factor 650IU
    D.3.2Product code BAX 111
    D.3.4Pharmaceutical form Powder and solution for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNVonicog alfa
    D.3.9.2Current sponsor codeBAX 111
    D.3.9.3Other descriptive nameHUMAN VON WILLEBRAND FACTOR
    D.3.9.4EV Substance CodeSUB22288
    D.3.10 Strength
    D.3.10.1Concentration unit IU international unit(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number650
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/10/814
    D.3 Description of the IMP
    D.3.1Product nameRecombinant von Willebrand Factor 1300IU
    D.3.2Product code BAX 111
    D.3.4Pharmaceutical form Powder and solution for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNVonicog alfa
    D.3.9.2Current sponsor codeBAX111
    D.3.9.3Other descriptive nameHUMAN VON WILLEBRAND FACTOR
    D.3.9.4EV Substance CodeSUB22288
    D.3.10 Strength
    D.3.10.1Concentration unit IU international unit(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1300
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name ADVATE 500 IU powder and solvent for solution for injection
    D.2.1.1.2Name of the Marketing Authorisation holderBaxter AG
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAdvate
    D.3.4Pharmaceutical form Powder and solvent for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNOCTOCOG ALFA
    D.3.9.1CAS number 139076-62-3
    D.3.9.4EV Substance CodeSUB16449MIG
    D.3.10 Strength
    D.3.10.1Concentration unit IU international unit(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number500
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name ADVATE 1000 IU powder and solvent for solution for injection
    D.2.1.1.2Name of the Marketing Authorisation holderBaxter AG
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAdvate
    D.3.4Pharmaceutical form Powder and solvent for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNOCTOCOG ALFA
    D.3.9.1CAS number 139076-62-3
    D.3.9.4EV Substance CodeSUB16449MIG
    D.3.10 Strength
    D.3.10.1Concentration unit IU international unit(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Hereditary severe von Willebrand Disease
    Forme grave de la maladie de von Willebrand héréditaire
    E.1.1.1Medical condition in easily understood language
    Inherited severe bleeding disorder (von Willebrand Disease)
    Forme grave d'une maladie hémorragique héréditaire (maladie de von Willebrand)
    E.1.1.2Therapeutic area Diseases [C] - Blood and lymphatic diseases [C15]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10047715
    E.1.2Term Von Willebrand's disease
    E.1.2System Organ Class 10010331 - Congenital, familial and genetic disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10055168
    E.1.2Term Von Willebrand's factor deficiency
    E.1.2System Organ Class 10010331 - Congenital, familial and genetic disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this study is to prospectively evaluate the annualized bleeding rate (ABR) for spontaneous bleeding episodes while on prophylactic treatment with rVWF and to compare it to the
    subject’s historical ABR for spontaneous bleeding episodes during on-demand treatment.
    L’objectif principal de cette étude est d’évaluer de manière prospective le taux annuel de saignement (TAS) pour les épisodes de saignement spontané se produisant durant le traitement prophylactique par un FvWr et de le comparer au TAS rétrospectif du patient pour les épisodes de saignement spontanés se produisant durant le traitement à la demande.
    E.2.2Secondary objectives of the trial
    Secondary Objectives are:
    - Additional efficacy assessments of prophylactic treatment
    - Safety and immunogenicity
    - Pharmacokinetics (PK)
    - Efficacy of the treatment of bleeding episodes
    Les objectifs secondaires sont les suivants :
    - Évaluations supplémentaires de l’efficacité du traitement prophylactique
    - Innocuité et immunogénicité
    - Pharmacocinétique (PK)
    - Efficacité du traitement pour les épisodes de saignement
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Subjects who meet ALL of the following criteria are eligible for this study:
    1. Subject has a documented diagnosis of severe VWD (baseline VWF:RCo <20 IU/dL) with a history of requiring substitution therapy with von Willebrand factor concentrate to control bleeding:
    a. Type 1 (VWF:RCo <20 IU/dL) or,
    b. Type 2A (as verified by multimer pattern), Type 2B (as diagnosed by genotype), Type 2M or,
    c. Type 3 (VWF:Ag ≤3 IU/dL).
    2. Diagnosis is confirmed by genetic testing and multimer analysis, documented in patient history or at screening.
    3. Subject currently receiving on-demand treatment for whom prophylactic treatment is recommended according to standard of care at the center.
    4. Has ≥3 documented spontaneous bleeds requiring VWF treatment during the past 12 months
    5. Availability of records to reliably evaluate type, frequency and treatment of bleeding episodes during 12 months of on-demand treatment prior to enrollment.
    6. Subject is ≥18 years old at the time of screening and has a body mass index ≥15 but <40 kg/m2.
    7. If female of childbearing potential, subject presents with a negative blood/urine pregnancy test at screening and agrees to employ adequate birth control measures for the duration of the study.
    8. Subject is willing and able to comply with the requirements of the protocol.
    Les patients qui remplissent TOUS les critères suivants sont éligibles à cette étude :
    1. Patient(e) présentant un diagnostic documenté de forme grave de la MvW (visite de référence : FvW:RCo < 20 UI/dl) avec en antécédent la nécessité d’un traitement substitutif par un concentré du facteur de von Willebrand pour contrôler les saignements :
    a. Type 1 (FvW:RCo < 20 UI/dl) ou
    b. Type 2A (vérifié par le profil des multimères), Type 2B (diagnostiqué par le génotype), Type 2M ou
    c. Type 3 (FvW:Ag ≤ 3 UI/dl).
    2. Diagnostic confirmé par une analyse génétique et une analyse des multimères, documentées dans les antécédents du/de la patient(e) ou au moment de la sélection.
    3. Patient(e) recevant actuellement un traitement à la demande pour lequel le traitement prophylactique est conseillé en fonction de la pratique courante du centre.
    4. Patient(e) ayant présenté ≥ 3 saignements spontanés documentés nécessitant un traitement par FvW au cours des 12 derniers mois.
    5. Patient(e) dont les données sont disponibles afin de faire une évaluation fiable du type, de la fréquence et du traitement des épisodes de saignement au cours des 12 mois de traitement à la demande avant l’inclusion.
    6. Patient(e) âgé(e) d’au moins 18 ans au moment de la sélection et possédant un indice de masse corporelle ≥ 15 mais < 40 kg/m2.
    7. S’il s’agit d’une patiente en âge d’avoir des enfants, elle doit présenter un test sanguin/urinaire de grossesse négatif au moment de la sélection et accepter l’utilisation d’une méthode de contraception adéquates durant toute la durée de l’étude.
    8. Patient(e) acceptant et capable de respecter les exigences du protocole.
    E.4Principal exclusion criteria
    Subjects who meet ANY of the following criteria are not eligible for this study:
    1. The subject has been diagnosed with Type 2N VWD, pseudo VWD, or another hereditary or acquired coagulation disorder other than VWD (e.g., qualitative and quantitative platelet disorders or elevated prothrombin time (PT)/international normalized ratio [INR] > 1.4).
    2. The subject has received prophylaxis treatment in the 12 months prior to screening (including those who received treatment once a month for menorrhagia but were not treated for any other bleeds).
    3. The subject is currently receiving prophylaxis treatment.
    4. The subject has a history or presence of a VWF inhibitor at screening.
    5. The subject has a history or presence of a FVIII inhibitor with a titer ≥0.4 BU (by Nijmegen modified Bethesda assay) or ≥0.6 BU (by Bethesda assay).
    6. The subject has a known hypersensitivity to any of the components of the study drugs, such as to mouse or hamster proteins.
    7. The subject has a medical history of immunological disorders, excluding seasonal allergic rhinitis/conjunctivitis, mild asthma, food allergies or animal allergies.
    8. The subject has a medical history of a thromboembolic event.
    9. The subject is HIV positive with an absolute Helper T cell (CD4) count <200/mm3.
    10. The subject has been diagnosed with significant liver disease as evidenced by any of the following:
    serum alanine aminotransferase (ALT) 5 times the upper limit of normal; hypoalbuminemia; portal vein hypertension (e.g., presence of otherwise unexplained splenomegaly, history of esophageal
    varices).
    11. The subject has been diagnosed with renal disease, with a serum creatinine level ≥2.5 mg/dL.
    12. The subject has a platelet count <100,000/mL at screening.
    13. The subject has been treated with an immunomodulatory drug, excluding topical treatment (e.g., ointments, nasal sprays), within 30 days prior to signing the informed consent.
    14. The subject is pregnant or lactating at the time of enrollment.
    15. Patient has cervical or uterine conditions causing menorrhagia or metrorrhagia (including infection, dysplasia).
    16. The subject has participated in another clinical study involving another investigational product (IP) or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study.
    17. The subject has a progressive fatal disease and/or life expectancy of less than 15 months.
    18. The subject is identified by the investigator as being unable or unwilling to cooperate with study procedures.
    19. The subject has a mental condition rendering him/her unable to understand the nature, scope and possible consequences of the study and/or evidence of an uncooperative attitude.
    20. The subject is in prison or compulsory detention by regulatory and/or juridical order
    21. The subject is member of the study team or in a dependent relationship with one of the study team members which includes close relatives (i.e., children, partner/spouse, siblings and parents) as well
    as employees.

    Delay criteria
    1. If the subject presents with an acute bleeding episodes or acute illness (e.g., influenza, flu-like syndrome, allergic rhinitis/conjunctivitis, non-seasonal asthma) the screening visit will be postponed until the subject has recovered.
    Les patients qui remplissent l’UN des critères suivants, quel qu’il soit, ne sont pas éligibles à cette étude :
    1. Patient(e) présentant un diagnostic de MvW de type 2N, de pseudo-MvW ou d’un trouble de la coagulation héréditaire ou acquis autre que la MvW (par ex. troubles plaquettaires qualitatifs ou quantitatifs ou temps de prothrombine (TP) élevé/rapport normalisé international (INR) > 1,4)
    2. Patient(e) ayant reçu un traitement prophylactique dans les 12 mois précédant la sélection (y compris les patients qui ont reçu un traitement une fois par mois pour une ménorragie mais qui n’étaient pas traités pour un autre saignement).
    3. Patient(e) recevant actuellement un traitement prophylactique.
    4. Patient(e) ayant des antécédents ou présentant des inhibiteurs du FvW au moment de la sélection.
    5. Patient(e) ayant des antécédents ou présentant des inhibiteurs du FVIII avec un titre ≥ 0,4 UB (par dosage Bethesda modifié selon Nijmegen) ou ≥ 0,6 UB (par dosage Bethesda).
    6. Patient(e) présentant une hypersensibilité connue à l’un des composants du produit expérimental, comme aux protéines de souris ou de hamster.
    7. Patient(e) présentant des antécédents médicaux de troubles immunologiques, à l’exception de la rhinite allergique saisonnière/de la conjonctivite/de l’asthme léger, des allergies alimentaires ou des allergies aux animaux.
    8. Patient(e) présentant des antécédents médicaux d’événements thromboembolique.
    9. Patient(e) positif/ve au VIH avec une numération absolue des lymphocytes T (CD4) auxiliaires < 200/mm3.
    10. Patient(e) présentant un diagnostic de maladie hépatique significative prouvé par les paramètres suivants : alanine aminotransférase (ALAT) sérique 5 fois supérieure à la limite normale ; hypoalbuminémie ; hypertension portale (par ex., présence de splénomégalie inexpliquée, antécédents de varices oesophagiennes).
    11. Patient(e) présentant un diagnostic de maladie rénale, avec un taux de créatinine sérique ≥ 2,5 mg/dl.
    12. Patient(e) présentant une numération plaquettaire < 100 000/ml au moment de la sélection.
    13. Patient(e) ayant été traité(e) par un traitement immunomodulateur, à l’exception des traitements topique (par ex., pommade, pulvérisateur nasal) dans les 30 jours précédant la signature du consentement.
    14. Patiente enceinte ou qui allaite lors de l’inclusion.
    15. Patiente présentant une affection du col de l’utérus ou une affection utérine entraînant une ménorragie ou une métrorragie (y compris infection et dysplasie).
    16. Patient(e) ayant participé à une étude clinique portant sur un produit expérimental (PE) ou un dispositif expérimental au cours des 30 jours précédant la date prévue de son inclusion, ou prévoyant de participer à une étude clinique portant sur un PE ou un dispositif expérimental au cours de cette étude.
    17. Patient(e) présentant une maladie progressive mortelle et/ou ayant une espérance de vie de moins de 15 mois.
    18. Patient(e) pour lequel/laquelle l’investigateur estime qu’il/elle n’est pas en mesure ou ne souhaite pas se conformer aux procédures de l’étude.
    19. Patient(e) présentant une pathologie mentale le/la rendant inapte à comprendre la nature, la portée et les conséquences possibles de l’étude et/ou montrant des signes non coopératif.
    20. Patient(e) en prison ou en détention obligatoire suite à une ordonnance réglementaire et/ou juridique.
    21. Patient(e) membre de l’équipe de l’étude ou en relation de dépendance avec l’un des membres de l’équipe de l’étude, incluant les proches (c’est-à-dire, enfants, partenaire/époux(se), frères et soeurs et parents) ainsi que les salariés.

    Critères entraînant un report
    1. Si le/la patient(e) présente des épisodes de saignement aigus ou une maladie aiguë (par exemple grippe, syndrome pseudo-grippal, rhinite allergique/conjonctivite, asthme non saisonnier), la visite de sélection sera reportée jusqu’à ce que le/la patient(e) soit remis(e).
    E.5 End points
    E.5.1Primary end point(s)
    Prospectively recorded ABR for spontaneous (not related to trauma) bleeding episodes during prophylactic treatment with rVWF and the subjects’ historical ABR for spontaneous bleeding episodes during on-demand treatment.
    Taux annuel de saignement (TAS) évalué de manière prospective pour les épisodes de saignement spontanés (qui ne sont pas liés à un traumatisme) se produisant durant le traitement prophylactique par un FvWr et TAS rétrospectif des patients pour les épisodes de saignement spontanés se produisant durant le traitement à la demande.
    E.5.1.1Timepoint(s) of evaluation of this end point
    On completion of 12 month prophylactic treatment.
    A la fin du traitement prophylactique de 12 mois.
    E.5.2Secondary end point(s)
    Efficacy
    - Number (proportion) of subjects with reduction of ABR for spontaneous (not related to trauma) bleeding episodes during prophylaxis relative to the subjects’ own historical ABR during on-demand treatment.
    - Number (proportion) of subjects with 0 bleeds during prophylactic treatment with rVWF.
    - Number of infusions and total weight adjusted consumption of rVWF and ADVATE (recombinant factor VIII/rFVIII) per month and per year during on-demand treatment.

    Safety
    - Adverse events (AEs)
    - Incidence of thromboembolic events
    - Incidence of severe hypersensitivity reactions
    - Development of neutralizing antibodies to VWF and FVIII
    - Development of total binding antibodies to VWF and FVIII
    - Development of antibodies to Chinese hamster ovary (CHO) proteins, mouse immunoglobulin G (IgG) and rFurin.

    Pharmacokinetic
    - Incremental recovery (IR), terminal half-life (T1/2), mean residence time (MRT), area under the curve/dose (AUC/dose), area under moment curve/dose (AUMC/dose), volume of distribution at steady state (Vss) and clearance (CL) based on Von Willebrand factor Ristocetin cofactor activity (VWF:RCo), Von Willebrand factor antigen (VWF:Ag), Von Willebrand collagen binding activity (VWF:CB) , INNOVANCE VWF Ac (exploratory assay) and time course (72 hours) of FVIII clotting activity (FVIII:C) levels.

    Efficacy of the treatment of bleeding episodes
    - Number of infusions of rVWF and ADVATE (rFVIII) per spontaneous bleeding episode.
    - Number of infusions of rVWF and ADVATE (rFVIII) per traumatic bleeding episode.
    - Weight-adjusted consumption of rVWF and ADVATE (rFVIII) per spontaneous bleeding episode.
    - Weight-adjusted consumption of rVWF and ADVATE (rFVIII) per traumatic bleeding episode.
    - Overall hemostatic efficacy rating at resolution of bleed
    Efficacité
    - Nombre (proportion) de patients présentant une réduction du TAS pour les épisodes de saignement spontanés (qui ne sont pas liés à un traumatisme) se produisant durant le traitement prophylactique par rapport au TAS rétrospectif propre au patient se produisant durant le traitement à la demande.
    - Nombre (proportion) de patients ne présentant aucun saignement durant le traitement prophylactique par un FvWr.
    - Nombre de perfusions et consommation totale de FvWr et d’ADVATE ajustée au poids (facteur VIII recombinant/FVIIIr) par mois et par an durant le traitement à la demande.

    Innocuité
    - Événements indésirables (EI)
    - Incidence des événements thromboemboliques
    - Incidence des réactions d’hypersensibilité sévères
    - Développement d’anticorps inhibiteur du FvW et du FVIII
    - Développement d’anticorps se liant au FvW et au FVIII
    - Développement d’anticorps contre les protéines d’ovaire de hamster chinois (Chinese Hamster Ovary, CHO), contre l’immunoglobuline G (IgG) de souris et contre la rFurine

    Pharmacocinétique
    - Récupération progressive (RP), demi-vie terminale (T1/2), temps de séjour moyen (TSM), aire sous la courbe/dose (ASC/dose), aire sous la courbe du moment/dose (ASCM/dose), volume de distribution à l’état d’équilibre (volume of distribution at steady state, Vss) et clairance (CL) en fonction de l’activité du cofacteur de la ristocétine du facteur de Willebrand (FvW:RCo), antigène du facteur de von Willebrand (FvW:Ag), activité de la liaison au collagène du facteur de von Willebrand (FvW:CB), test « INNOVANCE VWF Ac » (test exploratoire) et évolution (72 heures) des taux de l’activité coagulante du FVIII (FVIII:C).

    Efficacité du traitement des épisodes de saignement
    - Nombre de perfusions de FvWr et d’ADVATE (FVIIIr) par épisode de saignement spontané.
    - Nombre de perfusions de FvWr et d’ADVATE (FVIIIr) par épisode de saignement traumatique.
    - Consommation de FvWr et d’ADVATE (FVIIIr) ajustée au poids par épisode de saignement spontané.
    - Consommation de FvWr et d’ADVATE (FVIIIr) ajustée au poids par épisode de saignement traumatique.
    - Évaluation de l’efficacité hémostatique globale au moment de la résolution du saignement.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Efficacy parameters evaluated at end of study.
    Safety parameters evaluated within 24 hrs of awareness.
    Overall hemostatic efficacy rating at resolution of each bleed within 24 hrs.
    Paramètres d'efficacité évalués à la fin de l'étude.
    Paramètres d'innocuité évalués dans les 24 heures après la prise de connaissance.
    Evaluation globale de l'efficacité hémostatique à la résolution de chaque saignement dans les 24 h.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis Yes
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA25
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    Czech Republic
    Denmark
    Finland
    France
    Germany
    Italy
    Netherlands
    Sweden
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Dernière visite du dernier patient
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months10
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months10
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 14
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 4
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state4
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 11
    F.4.2.2In the whole clinical trial 18
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Subjects will be offered the option to continue to receive BAX111 in a long-term continuation study.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-02-14
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-03-14
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2020-07-06
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Sep 19 01:29:08 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA